Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhengye Biotechnology HoldingZYBT -3.08%20 PB Ratio is 2.52 as of Aug. 25, 2026, which is 6% below its 10-year median of 2.69. GuruFocus rates ZYBT with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 916 Drug Manufacturers companies, Zhengye Biotechnology Holding ranks worse than 62.23% on this metric.
The historical rank and industry rank for Zhengye Biotechnology Holding's PB Ratio or its related term are showing as below:
ZYBT'
s PB Ratio Range Over the Past 10 Years
Min: 0.86 Med: 2.69 Max: 16.3
Current: 2.52
During the past 5 years, Zhengye Biotechnology Holding's highest PB Ratio was 16.30. The lowest was 0.86. And the median was 2.69.
ZYBT's PB Ratio is ranked worse than 62.23% of 916
companies
in the Drug Manufacturers industry
Industry Median: 1.965
vs ZYBT: 2.52
During the past 12 months, Zhengye Biotechnology Holding's average Book Value Per Share Growth Rate was -9.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -6.00% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhengye Biotechnology Holding was -2.40% per year. The lowest was -6.00% per year. And the median was -4.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhengye Biotechnology Holding PB Ratio Related Terms
Zhengye Biotechnology Holding PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhengye Biotechnology Holding PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zhengye Biotechnology Holding's PB Ratio falls into.
Zhengye Biotechnology Holding PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhengye Biotechnology Holding (ZYBT) has a PB Ratio of 2.52 as of Aug. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhengye Biotechnology Holding and its competitors. This is near median its historical median of 2.69. Over the past decade, Zhengye Biotechnology Holding's PB Ratio has ranged from 0.86 to 16.30. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #570 out of 916 companies in the Drug Manufacturers industry, placing it in the top 62.2%.
Is Zhengye Biotechnology Holding's PB Ratio too high?
Zhengye Biotechnology Holding's current PB Ratio of 2.52 is near median its 10-year median of 2.69. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 16.30. The Drug Manufacturers industry median PB Ratio is 1.97. Zhengye Biotechnology Holding's value of 2.52 is 28.2% above this industry median. Based on the distribution chart, Zhengye Biotechnology Holding ranks #570 out of 916 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's PB Ratio compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #570 out of 916 companies for PB Ratio. This places Zhengye Biotechnology Holding in the lower half of its industry. The industry median PB Ratio is 1.97. Zhengye Biotechnology Holding's value of 2.52 is 28.2% above this benchmark. Historically, Zhengye Biotechnology Holding's own PB Ratio has ranged from 0.86 to 16.30 over the past decade. While the company's 10-year median is 2.69 vs. the industry median of 1.97, Zhengye Biotechnology Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhengye Biotechnology Holding's current PB Ratio of 2.52 is 28.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhengye Biotechnology Holding and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhengye Biotechnology Holding's current PB Ratio is 2.52, which is near median its own 10-year median of 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current PB Ratio of 2.52. The current PB Ratio is 2.52, which is near median its 10-year median of 2.69 and 28.2% above the Drug Manufacturers industry median of 1.97. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current PB Ratio is 2.52 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score
Get the complete analysis for ZYBT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYBT has been successfully added to your 
